Product Description
MORAb-109 is an antibody-drug conjugate (ADC) that targets human mesothelin. Mesothelin has been reported to be overexpressed in a number of cancers, including mesothelioma, non-small cell lung carcinoma (NSCLC), pancreatic, ovarian, colorectal, and gastric cancers. MORAb-109 consists of the humanized anti-human mesothelin antibody 345A12 HC15 LC4 that utilizes Eisai's site-specific conjugation technology RESPECT-L and was selected de novo as an antibody specifically for ADC generation. MORAb-109 also incorporates the tubulin-acting agent eribulin as the cytotoxic payload linked to the antibody through a cathepsin-cleavable self-immolative valine-citrulline linker. Eribulin is currently being investigated as an ADC payload in a folate-receptor alpha (FRA)-targeting ADC in an ongoing Ph 1 clinical trial (MOR202-J081-101). (Sourced from: https://www.annalsofoncology.org/article/S0923-7534(20)40689-1/fulltext)
Mechanisms of Action: Mesothelin Inhibitor
Novel Mechanism: Yes
Modality: Antibody Drug Conjugate
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Eisai
Company Location:
Company CEO: Haruo Naito
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|